Business Context and Reporting Period
This Form 8-K Current Report was filed by Neuralstem, Inc. on November 22, 2010. The filing discloses the entry into a material definitive agreement to establish an At-The-Market (ATM) equity offering program. Note: The request metadata references "Palisade Bio, Inc.," but the filing text explicitly identifies the registrant as Neuralstem, Inc.
Key Financial Metrics and Transaction Details
- Offering Size: Up to $20,000,000 of common stock.
- Sales Agent: Stifel, Nicolaus & Company, Incorporated.
- Compensation: The Sales Agent is entitled to a commission not exceeding 3.5% of the gross sales price per share.
- Sale Method: Ordinary brokers' transactions on the NYSE AMEX or at prevailing market prices.
- Registration: Pursuant to Form S-3 (No. 333-169847) filed on October 8, 2010.
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity metrics, as this report focuses solely on the new equity offering agreement.
Material Changes and Outlook
The primary material change is the authorization to sell equity shares from time to time to raise capital. The offering will terminate upon the earlier of the sale of all shares subject to the agreement or the termination of the Sales Agreement by either party. The company retains the option to sell shares to the Sales Agent as a principal under a separate terms agreement.
Investor Verification Checklist
- Verify the current share price and trading volume on the NYSE AMEX to assess the potential dilution impact of the $20 million offering.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Confirm the company's current cash position and burn rate to understand the urgency of this capital raise.
- Check for any subsequent filings regarding the actual volume of shares sold under this ATM program.